Patient-reported outcomes for older adults on CamAPS FX closed loop system

Aims Use of the CamAPS FX hybrid closed loop (CL) system is associated with improved time in range and glycated haemoglobin A1c across the age span, but little is known about its effects on patient-reported outcomes (PROs).Methods This open-label, randomized, multi-site study compared CamAPS FX to sensor-augmented pump (SAP) in a sample of older adults (= 60 years) with type 1 diabetes (T1D). Thirty-five older adults completed PROs surveys at the start of the study and after each period of 16 weeks using either CL or SAP. At the end of the study, 19 participated in interviews about their experiences with CL.Results Results examining the 16 weeks of CL use showed that the overall Diabetes Distress Scale score and two subscales (powerlessness and physician distress) improved significantly along with trust on the Glucose Monitoring Satisfaction Survey. User experience interview responses were consistent in noting benefits of 'improved glycaemic control' and 'worrying less about diabetes'.Conclusion In this sample of older adults with T1D who have previously shown glycaemic benefit, there are indicators of improved PROs and subjective user experience benefits.

Automated summary

The use of the CamAPS FX hybrid closed loop system has been found to improve time in range and glycated hemoglobin A1c levels across all age groups. However, there is limited research on its effects on patient-reported outcomes (PROs). This study compared CamAPS FX to sensor-augmented pump in older adults with type 1 diabetes. The results showed that the use of the CL system led to improved PROs and subjective user experience benefits.